Eli Lilly wants to gain on Novo Nordisk's obesity lead

US-based Eli Lilly has recently released strong data for its obesity drug, and is now investigating options to get it onto the market sooner than expected.

Photo: Mike Blake/Reuters/Ritzau Scanpix

While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.

”Based on our current data, we look forward to going through the data with the FDA [US Food and Drug Administration, -ed.] to discuss the possibility of receiving an accelerated pathway in this indication,” said Dan Skovronsky, chief scientific and medical officer of Eli Lilly, during a teleconference for analysts and investors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs